CN104244935A - 用于联合治疗的药物组合物 - Google Patents

用于联合治疗的药物组合物 Download PDF

Info

Publication number
CN104244935A
CN104244935A CN201380020405.5A CN201380020405A CN104244935A CN 104244935 A CN104244935 A CN 104244935A CN 201380020405 A CN201380020405 A CN 201380020405A CN 104244935 A CN104244935 A CN 104244935A
Authority
CN
China
Prior art keywords
obesity
tesofensine
pharmaceutically acceptable
acceptable salt
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380020405.5A
Other languages
English (en)
Chinese (zh)
Inventor
亨里克·比约克·汉森
莫滕·格伦内特
博·约尔特·本特森
拉尔斯·伊韦莱德-尼尔森
约尔延·布斯·拉森
克劳斯·松德格伦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aniona APS
Original Assignee
Neurosearch AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch AS filed Critical Neurosearch AS
Priority to CN201810575583.9A priority Critical patent/CN108434129A/zh
Priority to CN201810580312.2A priority patent/CN108853071A/zh
Publication of CN104244935A publication Critical patent/CN104244935A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380020405.5A 2012-02-16 2013-02-14 用于联合治疗的药物组合物 Pending CN104244935A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201810575583.9A CN108434129A (zh) 2012-02-16 2013-02-14 用于联合治疗的药物组合物
CN201810580312.2A CN108853071A (zh) 2012-02-16 2013-02-14 用于联合治疗的药物组合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261599623P 2012-02-16 2012-02-16
US61/599,623 2012-02-16
DKPA201270076 2012-02-16
DKPA201270076 2012-02-16
PCT/EP2013/052941 WO2013120935A1 (en) 2012-02-16 2013-02-14 Pharmaceutical compositions for combination therapy

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN201810580312.2A Division CN108853071A (zh) 2012-02-16 2013-02-14 用于联合治疗的药物组合物
CN201810575583.9A Division CN108434129A (zh) 2012-02-16 2013-02-14 用于联合治疗的药物组合物

Publications (1)

Publication Number Publication Date
CN104244935A true CN104244935A (zh) 2014-12-24

Family

ID=48983571

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201380020405.5A Pending CN104244935A (zh) 2012-02-16 2013-02-14 用于联合治疗的药物组合物
CN201810580312.2A Pending CN108853071A (zh) 2012-02-16 2013-02-14 用于联合治疗的药物组合物
CN201810575583.9A Pending CN108434129A (zh) 2012-02-16 2013-02-14 用于联合治疗的药物组合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201810580312.2A Pending CN108853071A (zh) 2012-02-16 2013-02-14 用于联合治疗的药物组合物
CN201810575583.9A Pending CN108434129A (zh) 2012-02-16 2013-02-14 用于联合治疗的药物组合物

Country Status (14)

Country Link
US (5) US9211271B2 (https=)
EP (1) EP2814473B1 (https=)
JP (1) JP6203760B2 (https=)
CN (3) CN104244935A (https=)
AU (1) AU2013220424B2 (https=)
CA (1) CA2864264C (https=)
DK (1) DK2814473T3 (https=)
EA (1) EA029543B1 (https=)
ES (1) ES2704987T3 (https=)
HR (1) HRP20190050T1 (https=)
LT (1) LT2814473T (https=)
PL (1) PL2814473T3 (https=)
SI (1) SI2814473T1 (https=)
WO (1) WO2013120935A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107666913A (zh) * 2015-03-03 2018-02-06 萨尼奥纳有限责任公司 特索芬辛，β‑受体阻滞剂组合制剂

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2704987T3 (es) * 2012-02-16 2019-03-21 Saniona As Composiciones farmacéuticas para terapia de combinación
WO2015099796A1 (en) * 2013-12-28 2015-07-02 Intel Corporation System and method for device action and configuration based on user context detection from sensors in peripheral devices
WO2017121432A1 (en) 2016-01-15 2017-07-20 Saniona A/S Tesofensine and metoprolol for treatment of hypertension
MX381130B (es) 2016-09-07 2025-03-12 Saniona As Composiciones de tesofensina.
MX2021008208A (es) 2019-01-07 2021-11-17 Saniona As Tesofensina para la reduccion del peso corporal para pacientes con sindrome de prader-willi.
CN110297826B (zh) * 2019-05-31 2020-12-11 南京理工大学 基于json动态解析卫星遥测数据的方法
CA3176183A1 (en) 2020-04-22 2021-10-28 Jorgen Drejer Treatment of hypothalamic obesity

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016197A1 (en) * 1991-03-18 1992-10-01 Sepracor Inc. Composition and method containing optically pure (s) metoprolol
WO2009080693A2 (en) * 2007-12-20 2009-07-02 Neurosearch A/S Pharmaceutical composition comprising tesofensine or its analogue and a beta blocker

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3238414B2 (ja) 1996-02-22 2001-12-17 ニューロサーチ・アクティーゼルスカブ トロパン―誘導体、その製造方法及びその使用方法
CA2553649A1 (en) 2004-01-22 2005-08-04 Neurosearch A/S Compounds for the sustained reduction of body weight
US20110118304A1 (en) 2007-11-20 2011-05-19 Neurosearch A/S Method for treating over-eating disorders
US20100317572A1 (en) 2007-12-20 2010-12-16 Neurosearch A/S Pharmaceutical composition comprising tesofensine or its analogue and an anti-obesity compound
WO2011100659A2 (en) 2010-02-12 2011-08-18 Kitov Pharmaceutical Ltd. Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs
ES2704987T3 (es) * 2012-02-16 2019-03-21 Saniona As Composiciones farmacéuticas para terapia de combinación
US9579288B2 (en) * 2015-03-03 2017-02-28 Saniona A/S Tesofensine and beta blocker combination formulations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016197A1 (en) * 1991-03-18 1992-10-01 Sepracor Inc. Composition and method containing optically pure (s) metoprolol
WO2009080693A2 (en) * 2007-12-20 2009-07-02 Neurosearch A/S Pharmaceutical composition comprising tesofensine or its analogue and a beta blocker

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107666913A (zh) * 2015-03-03 2018-02-06 萨尼奥纳有限责任公司 特索芬辛，β‑受体阻滞剂组合制剂
CN107666913B (zh) * 2015-03-03 2021-11-26 萨尼奥纳有限责任公司 特索芬辛，β-受体阻滞剂组合制剂

Also Published As

Publication number Publication date
US20170007557A1 (en) 2017-01-12
US20180185304A1 (en) 2018-07-05
EP2814473A1 (en) 2014-12-24
US20220016055A1 (en) 2022-01-20
US9387184B2 (en) 2016-07-12
US9211271B2 (en) 2015-12-15
HK1204946A1 (en) 2015-12-11
PL2814473T3 (pl) 2019-06-28
EA029543B1 (ru) 2018-04-30
US20160074344A1 (en) 2016-03-17
SI2814473T1 (sl) 2019-03-29
CN108434129A (zh) 2018-08-24
HRP20190050T1 (hr) 2019-03-08
CA2864264A1 (en) 2013-08-22
LT2814473T (lt) 2019-01-25
AU2013220424B2 (en) 2017-03-23
ES2704987T3 (es) 2019-03-21
JP6203760B2 (ja) 2017-09-27
CN108853071A (zh) 2018-11-23
WO2013120935A1 (en) 2013-08-22
EA201491532A1 (ru) 2015-01-30
JP2015508765A (ja) 2015-03-23
US20150025107A1 (en) 2015-01-22
EP2814473B1 (en) 2018-10-10
CA2864264C (en) 2020-05-05
DK2814473T3 (en) 2019-01-28
AU2013220424A1 (en) 2014-09-25

Similar Documents

Publication Publication Date Title
US20220016055A1 (en) Pharmaceutical Compositions For Combination Therapy
JP2010524989A (ja) 関節炎における痛みの治療のためのタペンタドール
JP2018515547A (ja) オピオイドとｎ−アシルエタノールアミンの組み合わせ
NZ547919A (en) Compounds for the sustained reduction of body weight
US20130310412A1 (en) Combinations of an Opioid/TLR4 Antagonist and a Direct-Acting Alpha-2 Adrenergic Agonist for Use in the Treatment of Pain
JP2012500248A (ja) 不安障害の治療
JP6227535B2 (ja) 脂質異常症の予防又は治療薬
JP2019524682A (ja) 抗うつ作用の速い発現のためのボルチオキセチン投与計画
HK1204946B (en) Pharmaceutical compositions for combination therapy
CN102858339B (zh) 用于治疗疼痛的血清素和去甲肾上腺素再摄取抑制剂与类鸦片激动剂的组合
US20250302802A1 (en) Methods and compositions
CA2840521A1 (en) Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation
EP2588093B1 (en) Tapentadol for use in the treatment of irritable bowel syndrome
WO2009080693A2 (en) Pharmaceutical composition comprising tesofensine or its analogue and a beta blocker
KR20220108123A (ko) 치매 환자의 행동 및 심리적 증상 치료
JP2013537232A (ja) 鎮痛をもたらすために、オピオイドの静脈内投与から、投薬アルゴリズムを用いたモルヒネおよびオキシコドンの経口共投与へと、患者の処置レジメンを変換する方法
RU2005127333A (ru) Средство для лечения синдрома раздраженного кишечника с преобладанием диареи

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20170406

Address after: Denmark and Rupp

Applicant after: ANIONA APS

Address before: Danish Heller Ukraine

Applicant before: Neurosearch A/S

TA01 Transfer of patent application right
RJ01 Rejection of invention patent application after publication

Application publication date: 20141224

RJ01 Rejection of invention patent application after publication